Google
Trusted Resources: News & Events
Latest announcements and gatherings
Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that it will present preclinical data comparing the effects of alternative dosing schedules for the selective HDAC1,2 inhibitor, ACY-957, on gamma globin (HBG) protein expression. In an oral presentation at the American Society of Hematology Annual Meeting (ASH) in San Diego, California, Jeffrey R. Shearstone, Ph.D., Associate Director of Biology at Acetylon, will present data demonstrating that treatment with ACY-957 was well tolerated in a 3-week dosing regime and led to greater than 50-fold increases of HBG mRNA and protein in non-anemic primates.
+myBinderRelated Content
-
Sickle Cell Disease Management & Complications: Sophie Lanzkron MD of Johns HopkinsStuck on sickle cell disease? We hammer ...
-
Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approachesSickle cell disease is an inherited diso...
-
Crizanlizumab lowers pain crises in at-risk sickle cell patients, ad-hoc trial data showNovartis’ investigational th...
-
Orphan Drugs for Sickle Vaso-occlusion: Dawn of a New Era of Targeted TreatmentWhile an orphan disease in the USA, sick...
-
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformGlobal biotherapeutics leader CSL Behrin...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for ...Emmaus Life Sciences, Inc., anno...
-
Let Your Light Shine: Yoga & MeditationPiedmont Health Services and Sickle Cell...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.